Molekule Group, Inc. (“Molekule” or the “Company”) (Nasdaq: MKUL),
a leading air purification technology company, today announced new
laboratory results that highlight the power of the Company’s
proprietary photoelectrochemical oxidation (“PECO”) technology and
its ability to destroy what conventional filters leave behind.
Three new studies were completed, including one from Florida
International University, that demonstrate that Molekule’s PECO
technology can safely destroy a vast range of indoor air
pollutants. PECO technology for air purification reacts with
ultraviolet light to oxidize pollutants, including viruses,
bacteria, mold, ozone, allergens, volatile organic compounds,
particles found in smoke and chemicals, and break them down into
harmless molecules.
“The new studies highlight the culmination of nearly three
decades of rigorous scientific research and development. PECO
technology not only captures but destroys pollutants at a
microscopic scale, ultimately helping people who suffer from
specific pollutant triggers breathe better air,” said Jaspreet
Dhau, Molekule’s vice president and head of research and
development. “In combating indoor air pollution, these results
illustrate our patented PECO technology's high-level efficiency in
critical scenarios like hospitals, as well as health care
facilities, classrooms, homes, businesses, public areas and other
essential indoor environments.”
The Florida International University preclinical study assessed
the differences in how air cleaned by a Molekule PECO-enhanced
device affects allergic reactions compared to air cleaned by
high-efficiency particulate absorbing (“HEPA”) filtration alone.
The study introduced cat dander, one of the most prominent indoor
allergens, into four chambers — two without a purifier (negative
control group and positive control group), one with a HEPA purifier
and one with a PECO purifier — three times a week for six weeks and
measured the reaction of 40 mice (10 per group) to the
allergen.
- Researchers found a measurable difference between Molekule’s
PECO technology and HEPA compared to control groups. The study
found a four-fold increase in the allergic response in control
groups compared to PECO and HEPA groups.
- The study also found that when looking at immune cells and
chemicals within the mice, the PECO group had a better outcome than
the HEPA group. Both were significantly better than the control
group.
The researchers hypothesized that mice in the PECO group
exhibited fewer cells associated with immune response because the
PECO filtration destroyed dander particles that the HEPA filtration
did not capture. The Company believes these results are promising
and intends to develop them further as part of human clinical
testing.
In June 2023, Molekule announced the results of an additional
study conducted jointly by Mercyhealth and The University of South
Florida, which measured the efficacy of Molekule’s PECO-powered air
purification on clinical recovery in mild or moderate COVID-19
patients.
- Patients in the Air Pro purifier group consisted of 18 females
with a mean age of 70 and candidates in the placebo group consisted
of 19 females with a mean age of 74.
- The research demonstrated that in-room devices with PECO
technology could help reduce the length of hospital stays by
approximately two days — a statistically significant length of
time.
Additionally, an imminent University of Nebraska Medical Center
study, which was commissioned by Molekule, assessed the impact of
coronavirus coming into contact with a Molekule PECO-enhanced
device.
- The results show the virus that causes COVID-19 oxidizes onto
the filter, leaving no evidence of its presence.
Molekule provides one of the largest ranges of proprietary and
patented FDA-cleared air purification devices available today. The
Company was founded in 2014 to tackle the adverse impacts of
polluted air in health care, education, hospitality and commercial
smart building applications.
For more information about how Molekule’s patented PECO
technology detects and destroys organic pollutants, please visit
molekule.com.
About Molekule References to “Molekule” herein
include Molekule Group, Inc. (Nasdaq: MKUL) and its consolidated
subsidiaries, including Molekule, Inc. Molekule is creating safer,
healthier indoor environments worldwide, starting with our most
essential resource: the air we breathe. Based on over 25 years of
research and development, the company creates scientifically tested
technology to improve indoor air quality for individuals,
businesses, schools, hospitals and organizations of all sizes.
Molekule's lineup of air purification solutions incorporates
medical-grade high-efficiency particulate air filtration and the
company’s patented photoelectrochemical oxidation — PECO —
technology, which surpasses traditional filters by effectively
destroying a wide range of pollutants, including volatile organic
compounds, mold, bacteria, viruses and allergens. These devices
have undergone rigorous assessments by third-party laboratories,
earning FDA clearance as medical devices. It’s all part of
Molekule’s vision of changing the world from the indoors out. For
more details, please visit molekule.com.
Forward-Looking Statements This press release
contains “forward-looking statements” within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based upon
current beliefs and expectations of our management and are subject
to known and unknown risks and uncertainties. Words or expressions
such as “expects,” “anticipates,” “intends,” “plans,” “believes,”
“estimates,” “may,” “will,” “projects,” “could,” “should,” “would,”
“seek,” “forecast,” or other similar expressions help identify
forward-looking statements. Factors that could cause actual events
to differ include, but are not limited to:
- general economic conditions in the markets where we
operate;
- the impact of the COVID-19 pandemic and related prophylactic
measures;
- expected timing of regulatory approvals and product
launches;
- non-performance of third-party vendors and contractors;
- risks related to our ability to successfully sell our products
and the market reception to and performance of our products,
including our new Molekule 360 indoor air quality management
solutions;
- the possibility that our products do not ultimately perform in
line with our testing or that prior test results may not be
replicated in future studies;
- our compliance with, and changes to, applicable laws and
regulations;
- our limited operating history;
- our ability to manage growth;
- our ability to obtain additional financing when and if
needed;
- our ability to expand product offerings;
- our ability to compete with others in our industry;
- our ability to protect our intellectual property;
- the ability of certain stockholders to determine the outcome of
matters that require stockholder approval;
- our ability to retain the listing of our common stock on
Nasdaq;
- our ability to defend against legal proceedings;
- success in retaining or recruiting, or changes required in, our
officers, key employees or directors;
- the ability to successfully integrate Molekule, Inc.
- the incurrence of unexpected costs, liabilities or delays
relating to our merger with Molekule, Inc.
- the risk that goodwill or identifiable intangible assets
(including such items recorded with respect to our merger with
Molekule, Inc.) could become impaired;
- our ability to successfully consummate acquisitions; and
- other economic, business, competitive, and regulatory factors
affecting the businesses of the Company generally, including but
not limited to those set forth in Molekule’s filings with the SEC,
including in the “Risk Factors” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations”
sections of Molekule’s latest annual report on Form 10-K, as
amended, and other SEC filings.
Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and actual results
may differ materially from those in the forward-looking statements
as a result of various factors. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable based on information currently available, we cannot
assure you that the expectations will prove to have been correct.
Accordingly, you should not place undue reliance on these
forward-looking statements. In any event, these statements speak
only as of the date of this release. We assume no obligation to
revise or update any of the forward-looking statements to reflect
events or circumstances after the date of this release or to
reflect new information or the occurrence of unanticipated
events.
Contacts
Media Contact Press@molekule.com
Investor Relations Contacts Ryan TylerChief Financial Officer,
MolekuleRyan.Tyler@molekule.com
MATTIO Communicationsmolekule@mattio.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f309a350-86b4-48b4-8d15-7357fa794a8b
Grafico Azioni Molekule (NASDAQ:MKUL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Molekule (NASDAQ:MKUL)
Storico
Da Dic 2023 a Dic 2024